KKR-backed Biosynth Carbosynth Acquires vivitide and Welcomes Ampersand Capital Partners as New Shareholder
Summary
LONDON--(BUSINESS WIRE)--KKR, a leading global investment firm, announced today the closing of its previously announced investment in Biosynth Carbosynth, an innovative life sciences reagents, custom synthesis and manufacturing services company, as well as Biosynth Carbosynth’s acquisition of vivitide, a global provider of custom peptides and antibodies for the life sciences and biotech industry. We will benefit greatly from vivitide’s strong U.S. presence, complementary portfolio of products and services, and entrepreneurial culture,” said Dr. Urs Spitz, CEO and President of Biosynth Carbosynth. “ This acquisition marks an important milestone in our ambitious journey to become a leading global partner providing critical materials to the biopharma and diagnostics industries. They are the supplier of choice for many in the pharmaceutical, life science, and diagnostic sectors and manufacture and source a vast range of chemical and biochemical products. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams.